Denali Therapeutics Q2 2022 Earnings Report
Key Takeaways
Denali Therapeutics reported a net loss of $58.8 million compared to a net loss of $60.7 million for the same period in the previous year. Collaboration revenue increased to $52.5 million, driven by milestone payments related to the TAK-920/DNL919 and SAR443820/DNL788 programs.
Phase 1 study of DNL919 (ATV:TREM2) is underway, marking the seventh program in clinical development.
Late-stage studies initiated for BIIB122 (LRRK2 inhibitor) and SAR443820 (RIPK1 inhibitor) in Parkinson’s disease and ALS, respectively.
Data from ongoing studies of DNL310 (ETV:IDS) in Hunter syndrome and DNL343 (eIF2B activator) in ALS will be presented in the second half of the year.
Sanofi began dosing with SAR443820 in the Phase 2 HIMALAYA study for ALS, triggering a $40 million milestone payment to Denali.